The serum levels of Galectin-3 inpatients with ovarian cancer and its clinica l diagnostic value

MA Guoqing; LAN Ling; LI Yan

doi:10.3969/j.issn.1002-7386.2017.02.05

Abstract：Objective To investigate the serum levels of Galectin-3 and its clinical diagnostic value in patients with primary ovarian cancer .Methods A total of 92 patients with ovarian cancer who were treated from June 2010 to December 2015were enrolled in the study as observation group , moreover,benign ovarian tumor group ( n =44) and control group (43 healthy subjects) were set up.The general conditions of patients were recorded in their first visiting ,and the serum levels of CA125 ,HE4 and Galectin-3 were detected .Moreover the correlation between Galectin-3 and clinical parameters was analyzed . The ROC curve was used to evaluate the diagnositc valve of Galectin-3 in ovarian cancer .Results The serum levels of Galectin-3 in observation group [(1.64 ±0.68) ng/ml] were significantly higher than those in benign ovarian tumor group [(0.86 ±0.42) ng/ml] and control group [0.69 ±0.20)ng/ml],and the serum levels of Galectin-3 were even higher in patients with higher clinical stage and with distant metastases .In observation group ,Galectin-3 was positively correlated to CA125 ( r =0.431, P <0.01),HE4 ( r =0.331, P <0.01) and clinical stages (RS=0.431, P <0.01).The AUC of Galectin-3 in single index diagnosis group was 0.861 (95%CI:0.804~0.918),however,which in combination diagnosis of Galectin-3 with HE4 and CA125 was 0.916 (95%CI:0.871 ~0.961).Conlcusion The serum levels of Galectin-3 are obviously increased in patients with ovarian cancer ,moreover ,which are closely correlated with clinical stages .The combination diagnosis of Galectin-3 with CA125 and HE4 can enhance diagnostic efficacy for ovarian cancer .